Key result
In newly diagnosed nonvalvular atrial fibrillation patients in the Africa/Middle East region, dabigatran use was associated with a low stroke incidence rate of 0.53 per 100 patient-years over 2 years.
Why the study?
Data on the epidemiology and treatment of atrial fibrillation in the Africa/Middle East region were limited, and the use and effectiveness of novel oral anticoagulants in real-world clinical practice had not been evaluated.
Observational (n=600)
Yes
In real-world practice in the Africa/Middle East region, dabigatran use for newly diagnosed nonvalvular atrial fibrillation showed high persistence and low rates of stroke and major bleeding over 2 years.
Provides first regional GLORIA-AF insights on anticoagulant use in AF; leaves optimal strategies open pending further data.
BACKGROUND: Data on the epidemiology and treatment of atrial fibrillation in the Africa/Middle East region are limited, and the use of novel oral anticoagulants and their effectiveness in real-world clinical practice has not been evaluated. METHODS AND RESULTS: This study used prospectively collected data from the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation (GLORIA-AF) to describe anticoagulant use and outcomes in Africa and the Middle East. Baseline characteristics of patients newly diagnosed with nonvalvular atrial fibrillation from Lebanon (242 patients, 40.3%), Saudi Arabia (236 patients, 39.3%), United Arab Emirates (87 patients, 14.5%), and South Africa (35 patients, 5.8%) were described, and clinical outcomes were investigated for all patients in this region who received dabigatran.In newly diagnosed patients (having a diagnosis within the last three months) with nonvalvular atrial fibrillation in Africa and the Middle East, the observed uptake of non-vitamin K oral anticoagulants was high in the first years following their availability; dabigatran was the most commonly used antithrombotic agent (314/600 patients), and only 1.5% of patients did not receive any antithrombotic therapy. Use of dabigatran was associated with a high persistence rate (>88% at 24 months) and low incidence rates of stroke, myocardial infarction, major bleeding, and all-cause mortality after 2 years of follow-up. CONCLUSIONS: NCT01937377 (https://clinicaltrials.gov/ct2/show/NCT01937377).
No takes yet. Share an insight, caveat, or question.
Azar et al. (2021) conducted an observational in Nonvalvular atrial fibrillation (n=600). Dabigatran was evaluated on Stroke incidence rate per 100 patient-years (95% CI 0.11-1.56). In newly diagnosed nonvalvular atrial fibrillation patients in the Africa/Middle East region, dabigatran use was associated with a low stroke incidence rate of 0.53 per 100 patient-years over 2 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: